Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

Next Generation Radiotheranostics Promoting Precision Medicine.

In Annals of oncology : official journal of the European Society for Medical Oncology

Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.

Pomykala K L, Hadaschik B A, Sartor O, Gillessen S, Sweeney C J, Maughan T, Hofman M S, Herrmann K

2023-Mar-14

(177)Lu-Dotatate, (177)Lu-PSMA, endoradiotherapy, positron emission tomography, radiotheranostics, targeted radioligand therapy